These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25786554)

  • 1. TREATMENT WITH CINACALCET INCREASES PLASMA ADIPONECTIN CONCENTRATION IN HEMODIALYZED PATIENTS WITH CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYROIDISM.
    Kuczera P; Adamczak M; Machnik G; Okopień B; Wiecek A
    Endocr Pract; 2015 Jul; 21(7):743-9. PubMed ID: 25786554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of Serum Total and Free Testosterone Concentrations in Male Chronic Hemodialysis Patients with Secondary Hyperparathyroidism in Response to Cinacalcet Treatment.
    Kuczera P; Adamczak M; Wiecek A
    Kidney Blood Press Res; 2016; 41(1):1-8. PubMed ID: 26751580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism.
    Kuczera P; Adamczak M; Machnik G; Okopien B; Wiecek A
    Nephron; 2018; 139(4):286-292. PubMed ID: 29879701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Więcek A
    BMC Nephrol; 2016 Nov; 17(1):176. PubMed ID: 27846800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism.
    Hryszko T; Brzosko S; Rydzewska-Rosolowska A; Koc-Zorawska E; Mysliwiec M
    Int Urol Nephrol; 2012 Oct; 44(5):1479-86. PubMed ID: 21874285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
    Pérez-Ricart A; Galicia-Basart M; Alcalde-Rodrigo M; Segarra-Medrano A; Suñé-Negre JM; Montoro-Ronsano JB
    PLoS One; 2016; 11(9):e0161527. PubMed ID: 27588942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
    Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
    Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis.
    Imafuku T; Tanaka M; Tokunaga K; Miyamura S; Kato H; Tanaka S; Nakano T; Hirata K; Kadowaki D; Maeda H; Matsushita K; Otagiri M; Komaba H; Fukagawa M; Watanabe H; Maruyama T
    Biol Pharm Bull; 2020; 43(10):1583-1590. PubMed ID: 32999168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.
    Sohn WY; Portale AA; Salusky IB; Zhang H; Yan LL; Ertik B; Shahinfar S; Lee E; Dehmel B; Warady BA
    Pediatr Nephrol; 2019 Jan; 34(1):145-154. PubMed ID: 30141180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
    Frazão JM; Messa P; Mellotte GJ; Geiger H; Hagen EC; Quarles LD; Kerr PG; Baños A; Dehmel B; Urena P
    Clin Nephrol; 2011 Sep; 76(3):233-43. PubMed ID: 21888861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
    Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
    Ngamkam J; Vadcharavivad S; Areepium N; Auamnoy T; Takkavatakarn K; Katavetin P; Tiranathanagul K; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
    Sci Rep; 2021 Sep; 11(1):18006. PubMed ID: 34504264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
    Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
    Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
    Goodman WG; Ward DT; Martin KJ; Drayer D; Moore C; Xu J; Lai J; Chon Y; Nemeth EF
    J Am Soc Nephrol; 2022 Jan; 33(1):201-212. PubMed ID: 34732508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
    Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
    Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.
    Ruderman I; Smith ER; Toussaint ND; Hewitson TD; Holt SG
    BMC Nephrol; 2018 May; 19(1):113. PubMed ID: 29764395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects.
    Padhi D; Langman CB; Fathallah-Shaykh S; Warady BA; Salusky IB; Lee E; Wang C; Posvar E
    Pediatr Nephrol; 2012 Oct; 27(10):1953-9. PubMed ID: 22639045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.